Old Web
English
Sign In
Acemap
>
authorDetail
>
Ademi Santiago-Walker
Ademi Santiago-Walker
GlaxoSmithKline
MEK inhibitor
Trametinib
Medicine
Cancer research
Mutation
5
Papers
155
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
2018
Investigational New Drugs
C. Aghajanian
Katherine M. Bell-McGuinn
Howard A. Burris
Lillian L. Siu
Lee Ann Stayner
Jennifer J. Wheler
David S. Hong
Carla Kurkjian
Shubham Pant
Ademi Santiago-Walker
J. L. Gauvin
Joyce M. Antal
Joanna B. Opalinska
Shannon R. Morris
Jeffrey R. Infante
Show All
Source
Cite
Save
Citations (20)
Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C).
2017
Journal of Clinical Oncology
Dirk Schadendorf
Keith T. Flaherty
Peter Hersey
Paul Nathan
Claus Garbe
Mohammed M. Milhem
Lev V. Demidov
Jessica C. Hassel
Piotr Rutkowski
Peter Mohr
Reinhard Dummer
Uwe Trefzer
James Larkin
Jochen Utikal
Michelle Casey
Ademi Santiago-Walker
Laurie Sherman
Anne-Marie Martin
Frank S. Wu
Caroline Robert
Show All
Source
Cite
Save
Citations (1)
Genetic and molecular biomarker characterization of KRAS mutant non-small cell lung carcinoma (NSCLC) tumors.
2017
Journal of Clinical Oncology
Li Liu
Yuan Liu
Ademi Santiago-Walker
Hong Shi
Vivian Zhang
Ashley M. Hughes
Carmen Arenas-Elliott
Lori Roadcap
Anne-Marie Martin
Tona M. Gilmer
Show All
Source
Cite
Save
Citations (0)
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
2016
Clinical Cancer Research
Ademi Santiago-Walker
Robert C. Gagnon
Jolly Mazumdar
Michelle Casey
Georgina V. Long
Dirk Schadendorf
Keith T. Flaherty
Richard Kefford
Axel Hauschild
Patrick Hwu
Patricia Haney
Anne O'Hagan
Jennifer Carver
Vicki L. Goodman
Jeffrey J. Legos
Anne-Marie Martin
Show All
Source
Cite
Save
Citations (134)
Association between circulating hepatocyte growth factor (HGF) and clinical response across five studies with the BRAF inhibitor dabrafenib or MEK inhibitor trametinib.
2014
Journal of Clinical Oncology
Ademi Santiago-Walker
Robert C. Gagnon
Jennifer Carver
C. Martin Curtis
Patricia Haney
Shonda M Little
Anne O'Hagan
Vicki L. Goodman
Jeffrey J. Legos
Kiran Patel
Anne-Marie Martin
Show All
Source
Cite
Save
Citations (0)
1